The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

In this section you'll find photographic features that explore holidays and photography courses, details about members meetings, trials and tribulations of installing new software along with ...

From lens focal lengths and fill-flash to portraits, macro or stunning landscapes there are techniques for everyone. Learn how to use metering, considering composition and shoot everything from ...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...